-
Mashup Score: 4
The BCL-2 inhibitor lisaftoclax was well tolerated and produced encouraging responses in relapsed/refractory multiple myeloma when given in combination with Pd.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 4
The BCL-2 inhibitor lisaftoclax was well tolerated and produced encouraging responses in relapsed/refractory multiple myeloma when given in combination with Pd.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Lisaftoclax Plus Pd Yields High ORRs and Shows Encouraging Safety Profile in RRMM @ASH_hematology #ASH24 #mmsm #oncology #MedEd https://t.co/0uMcJ8YMes
-
-
Mashup Score: 4
The BCL-2 inhibitor lisaftoclax was well tolerated and produced encouraging responses in relapsed/refractory multiple myeloma when given in combination with Pd.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Lisaftoclax Plus Pd Yields High ORRs and Shows Encouraging Safety Profile in RRMM @ASH_hematology #ASH24 #mmsm #oncology #MedEd https://t.co/0uMcJ8YMes
-
Lisaftoclax Plus Pd Yields High ORRs and Shows Encouraging Safety Profile in RRMM @ASH_hematology #ASH24 #mmsm #oncology #MedEd https://t.co/0uMcJ8YMes